

## **Amendments to the Claims**

The following listing of claims will replace all prior versions, and listings, of claims in the application.

### **Listing of Claims**

Claim 1-3 (canceled)

Claim 4 (previously presented) The antibody Mab 1F1, secreted by the hybridoma line G3BP 1F1 1D1 deposited on 9 June 1998 at the C.N.C.M. under the number I-2038.

Claim 5-6 (canceled)

Claim 7 (currently amended) Pharmaceutical composition comprising a therapeutically effective quantity of the monoclonal antibodies according to claim [[13 or]] 14, the said quantity being therapeutically effective for inducing apoptosis in tumor cells.

Claim 8 (currently amended) Hybridoma line capable of secreting monoclonal antibodies according to claim [[13 or]] 14.

Claim 9 (original) Hybridoma line G3BP 1F1 1D1 deposited on 9 June 1998 at the C.N.C.M. under the deposit number I-2038.

Claim 10 -13 (canceled)

Claim 14 (previously presented) Monoclonal antibody directed against the protein of SEQ ID NO:1 and capable of inducing apoptosis in various types of tumor cells, wherein the antibody recognizes an epitope between amino acids 22-34 of SEQ ID NO:1.